| Outcome Measures: |
Primary: eGFR reduction, Incidence of eGFR reduction by 30% or more at 24 months, 24 months | Secondary: eGFR, Changes in eGFR over time, 24 months|Urine protein-to-creatinine (UPC) ratio, Changes in urine protein-to-creatinine (UPC) ratio over time, 24 months|End-stage kidney disease (ESKD), Incidence rates of end-stage kidney disease (ESKD), 24 months|Fasting glucose, Changes in fasting glucose over time, 24 months|Hba1c, Changes in Hba1c over time, 24 months|Lipids, Changes in lipids over time, 24 months|Anti-dsDNA, Changes in anti-dsDNA over time (measured by ELIZA), 24 months|C3, Changes in C3 over time (measured by nephelometry), 24 months|Memory B cells, Changes in memory B cells over time (measured by flow cytometry), 24 months|miR-148a, Changes in miR-148a over time (measured by qPCR using blood samples), 24 months|BACH1, Changes in BACH1 over time (measured by qPCR using blood samples), 24 months|BACH2, Changes in BACH2 over time (measured by qPCR using blood samples), 24 months|PAX5, Changes in PAX5 over time (measured by qPCR using blood samples), 24 months|Clinical relapses, Occurrence of clinical relapses (renal and extra-renal relapses), 24 months|Urinary tract infection, Incidence rates of urinary tract infection, 24 months|Ketoacidosis, Incidence rates of ketoacidosis, 24 months|genital infection, Incidence rates of genital infection, 24 months|Acute kidney injury, Incidence rates of acute kidney injury, 24 months
|
